(NASDAQ:EDIT) in a report released on Wednesday. "This was the result of higher than expected collaborative revenue, lower than estimated operating expenses and higher than estimated shares outstanding.", the firm's analyst commented. As per WSJ analytic report, EDIT for the Q3 this year, the current consensus earnings per share trend estimates was $-0.53, while for one month ago estimates was $-0.60.
Over the last 5 years, Analysts are expecting EPS growth rates to be at -47.00% this quarter and EPS estimate for next year reflect -4.30% growth rate.
According to Zacks, "Editas Medicine, Inc.is a genome editing company".
Editas Medicine, Inc. (NASDAQ:EDIT) share price increased in the last trading session with a previous 52-week high of $29.20. The company reported ($0.65) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.64) by $0.01. Editas Medicine had a negative net margin of 2,091.36% and a negative return on equity of 69.21%. The average volume stands around 0.79 million shares. Over the last five days, shares have managed 13.73% gains and now is down -0.54% since hitting its 200-day moving average of $18.97. The company's sales was down 8.8% on a YOY basis.
A number of other equities analysts have also recently weighed in on EDIT. Zacks Investment Research raised shares of Editas Medicine from a hold rating to a buy rating and set a $19.00 price target for the company in a research report on Wednesday, July 12th. Oppenheimer Holdings, Inc. reiterated a "market perform" rating on shares of Editas Medicine in a research note on Tuesday, July 18th. Finally, SunTrust Banks, Inc. started coverage on Editas Medicine in a report on Thursday, July 13th. Editas Medicine has a consensus rating of "Buy" and a consensus target price of $25.03. Creative Planning's holdings in Editas Medicine were worth $153,000 at the end of the most recent reporting period. If you are accessing this piece of content on another site, it was illegally copied and reposted in violation of USA and worldwide trademark and copyright legislation. The firm had revenue of $3.10 million for the quarter, compared to analyst estimates of $2.20 million. The shares were purchased at an average cost of $14.07 per share, with a total value of $492,450.00. Following the transaction, the director now owns 35,000 shares in the company, valued at $492,450.
In related news, insider Gerald Frank Cox bought 4,000 shares of the company's stock in a transaction on Friday, June 2nd.
On 3/15/2017 Alexandra Glucksmann, COO, sold 1,000 with an average share price of $26.41 per share and the total transaction amounting to $26,410.00. Boris Nikolic, Director disclosed the purchase of 35,000 shares of (EDIT). Bank of New York Mellon Corp now owns 142,122 shares of the company's stock valued at $2,385,000 after buying an additional 78,632 shares during the period. The company's institutional ownership is monitored at 80.8 percent. Fox Run Management L.L.C. purchased a new position in Editas Medicine during the first quarter worth $272,000. Morgan Stanley now owns 308,909 shares of the company's stock valued at $6,895,000 after buying an additional 100,585 shares in the last quarter. Pacad Investment Ltd. purchased a new stake in Editas Medicine during the second quarter valued at about $287,000. The average numbers of shares are traded in a security per day, during the recent 3-month period. Barrett Asset Management LLC purchased a new stake in shares of Editas Medicine during the first quarter valued at about $223,000. FMR LLC now owns 5,901,489 shares of the company's stock valued at $131,721,000 after buying an additional 403,099 shares in the last quarter. Editas Medicine, Inc. (NASDAQ:EDIT) has noticeable measure of stock volatility, for this average true range is an exponential moving average (14 trading days) of the True Ranges. The stock was trading on above-average volume. The Firm has ATR of 1.08 that is explaining range of a day's trading is high-low; ATR expands it to yesterday's closing price if it was outside of recently's range. It has a market cap of $1.56 Billion. The company has a 50 day moving average of $17.20 and a 200-day moving average of $19.02. The Company operates through developing and commercializing genome editing technology segment.